Marks Group Wealth Management Inc Sells 482 Shares of Johnson & Johnson $JNJ

Marks Group Wealth Management Inc decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 10.9% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,930 shares of the company’s stock after selling 482 shares during the quarter. Marks Group Wealth Management Inc’s holdings in Johnson & Johnson were worth $600,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Brighton Jones LLC boosted its position in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares during the last quarter. Wealth Group Ltd. bought a new position in shares of Johnson & Johnson during the first quarter worth $218,000. NewSquare Capital LLC boosted its position in shares of Johnson & Johnson by 266.9% during the first quarter. NewSquare Capital LLC now owns 1,064 shares of the company’s stock worth $176,000 after acquiring an additional 774 shares during the last quarter. Range Financial Group LLC boosted its position in shares of Johnson & Johnson by 18.9% during the first quarter. Range Financial Group LLC now owns 15,886 shares of the company’s stock worth $2,635,000 after acquiring an additional 2,529 shares during the last quarter. Finally, CHICAGO TRUST Co NA raised its stake in Johnson & Johnson by 0.5% during the first quarter. CHICAGO TRUST Co NA now owns 17,890 shares of the company’s stock valued at $2,967,000 after purchasing an additional 93 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on JNJ shares. UBS Group set a $198.00 price target on shares of Johnson & Johnson in a research note on Friday. Bank of America upped their price target on shares of Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. HSBC upped their price target on shares of Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price target for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Finally, The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a research note on Friday, September 19th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $189.88.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $188.95 on Wednesday. The firm has a 50-day moving average price of $177.04 and a 200-day moving average price of $163.18. The firm has a market capitalization of $455.06 billion, a PE ratio of 20.21, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $189.92.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the business earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.